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Abstract: Neglected Tropical Diseases (NTDs) marked out for disease elimination provide a lens 
through which to explore the changing status of diagnosis in global health. This paper reports on 
the findings of a scoping review, which set out to explore the main debates around diagnosis for the 
elimination of NTDs, including the multiple roles diagnostic technologies are being ascribed and 
the ideal characteristics of tests. It also attempts to summarise the state of diagnosis for three NTDs 
with elimination goals. The review places special emphasis on point-of-care testing in 
acknowledgement of the remote and underserved areas where NTDs proliferate. Early NTD 
campaigns were largely focused on attack phase planning, whereby a similar set of interventions 
could be transplanted anywhere. Now, with elimination goals in sight, strategies must be tailored 
to local settings if they are to attain and sustain success. Diagnostic data helps with local adaptation 
and is increasingly used for programmatic decision-making. The review finds that elimination goals 
reframe whom diagnosis is for and the myriad roles diagnostics can play. The exigencies of 
elimination also serve to highlight deficiencies in the current diagnostic arsenal and development 
pipeline for many NTDs. Moving forward, a guiding framework is needed to drive research and 
stimulate investment in diagnosis to support NTD goals. 
Keywords: diagnosis; neglected tropical disease; disease elimination; point-of-care diagnostics 
 
1. Introduction 
The current COVID-19 crisis has brought the importance of diagnosis into sharp relief, but even 
prior to this, the status of diagnosis in global health has been changing. The publication of the first 
Essential Diagnostic List (EDL) in 2018 signalled a turning point, suggesting for the first time that 
diagnostics could come to occupy a comparative status in global health as pharmaceuticals [1]. Other 
key milestones include the launch of the Foundation for Innovative New Diagnostics (FIND), the 
establishment of the Global Diagnostics Forum, and the launch of the Lancet Commission on 
Diagnostics. In 2019, the World Health Organisation (WHO) convened a new Diagnostic Technical 
Advisory Group for Neglected Tropical Diseases (NTDs), and in 2020 plans to launch a revised “NTD 
Roadmap”, for the period 2021–2030, assigning diagnosis a pivotal role [2]. This breaks with the 
peripheral position afforded diagnosis in the last “NTD Roadmap” [3], which served to formalise an 
ambitious disease elimination and eradication agenda for many of the named diseases but largely 
prioritised pharmaceutical solutions. 
There is hardly a better lens through which to view diagnosis’ changing status than through 
NTDs. Toward the beginning of the last decade, NTD campaigns were best described as a “steam 
roller” of drugs crossing the African continent (Prof. Alan Fenwick referring to mass drug 
administration at the International Society for Neglected Tropical Diseases conference on 12th 
February 2013). Today, with disease elimination and eradication goals in sight for many diseases, 
approaches have grown more nuanced and sophisticated. Prevention has been afforded a much 
bigger role (as demonstrated by WHO strategy papers on water, sanitation and hygiene, and vector 
control [4,5]). In addition, real-time data is increasingly informing programmatic decision-making, 
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thanks to data platforms like ESPEN Collect (Expanded Special Project for Elimination of Neglected 
Tropical Diseases) and Tropical Data (the data-collection initiative supporting trachoma elimination) 
[6,7]. This data is being used to map the geographical spread of NTDs; to determine whether 
programmes need to scale up or scale down (or change tack); and, once disease goals are achieved, 
to help programmes sustain success (this list is not exhaustive). Diagnosis is playing an increasingly 
important role in this data revolution, with the rigours of elimination goals both reframing the myriad 
roles diagnostic technologies can play and highlighting deficiencies in the current diagnostic arsenal 
and development pipeline. 
Reporting on the results of a scoping review and supporting discourse analysis, this paper 
attempts to synthesise the main debates around diagnosis for the elimination of NTDs, exploring the 
multiple roles diagnostics are being ascribed, the ideal characteristics of tests, and the state of 
diagnostics for three foci NTDs. 
The paper boasts an express interest in field applicable or point-of-care testing. This is in 
recognition of the settings where NTDs predominate—where basic health infrastructure is sparse or 
wholly absent [8]. New point-of-care testing technologies have great potential for both improving 
access to care and generating high-quality epidemiological data for NTD prevalence in the under-
resourced settings where NTDs are commonly found. 
NTDs and Disease Elimination 
In the new millennium, the case was made that a number of tropical infections should be taken 
forward as a group by virtue of their “neglected” status and shared geographic overlap, and because 
cost savings and synergies could be levied if the different disease programmes acted together [9,10]. 
The resulting categorisation—Neglected Tropical Disease (NTD)—has subsequently become a 
successful “brand identity” [11]. 
The WHO helped create cohesion around NTDs by naming an initial grouping of 17 diseases in 
2010 [12] and then incorporating these into a joint framework for action in 2012: the “NTD Roadmap” 
[3]. The Roadmap contains targets relating to the NTDs (in their previous incarnations as 
unconnected diseases) based on existing World Health Assembly resolutions [12] (pp. 155–157). The 
Roadmap served to collate these targets—which include control, elimination, and eradication goals—
in one umbrella document, and together with the London Declaration on NTDs [13], mobilised action 
in pursuit of an overarching 2020 agenda. The revised Roadmap to be launched in 2020 will move 
the focus on to 2030, better aligning the NTDs with the Sustainable Development Goals [2]. While 
both Roadmaps have presented the NTDs as a collective grouping, it is significant that most disease 
programmes continue to operate in a largely vertical manner (with their own budgets and reporting 
systems). 
Successful campaigning has resulted in increased attention and resources for NTDs. Aligning 
the diseases with global goals—Millennium Development Goals, Sustainable Development Goals, 
and disease-specific targets like disease elimination—has further motivated action [9,14,15]. 
The history of global health in the 20th and 21st centuries attests to widespread attraction to the 
concept of disease eradication. The intuitive appeal is simple: frontload investment now in order to 
save money on prevention and control in the future. This style of thinking took root at the Rockefeller 
Foundation before WWII, then was carried on after the war by the newly formed WHO, which led 
campaigns against yaws, yellow fever, malaria, and smallpox [16]. As an approach, however, 
eradication fell out of favour with the failure of the malaria eradication programme in the 1950s. 
Various conferences and initiatives convened in the last 20 years have served to reignite the concept 
(the 1997 Dahlem Workshop on the Eradication of Infectious Diseases; the 1998 Conference on Global 
Disease Elimination and Eradication as Public Health Strategies; the International Taskforce for 
Disease Eradication). Many candidates have been discounted for eradication, stimulating debate that 
has resulted in new categorisations of disease—namely, diseases with the potential to be eradicated 
in the future, and diseases which could feasibly be eliminated within a specified area in the short- to 
medium-term [17]. This widening of the definitional net has seen the number of diseases targeted for 
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disease elimination swell, a trend demonstrated by the range of NTDs marked out for elimination in 
the 2012 “NTD Roadmap” (Table 1). 
Table 1. Neglected Tropical Disease (NTD) elimination targets [3] (p. 19). 
Disease Target 
Chagas Disease Regional elimination 
Human African Trypanosomiasis Global elimination 
Human Rabies Regional elimination 
Leprosy Global elimination 
Lymphatic Filariasis Regional elimination 
Onchocerciasis Regional elimination 
Schistosomiasis Regional elimination 
Trachoma Global elimination 
Visceral Leishmaniasis Global elimination 
One outcome of this proliferation of targets has been to expose the terminological confusion 
around such goal setting. In an attempt to provide clarity around the three interrelated terms, disease 
eradication, elimination, and control, Molyneux, Hopkins, and Zagaria endorsed the definitions 
presented in Box 1. 
Box 1. Glossary of control, elimination, and eradication terminology [18]. 
Control: Reduction of disease incidence, prevalence, morbidity or mortality to a locally 
acceptable level as a result of deliberate efforts. Continued intervention measures are 
required to maintain the reduction. 
Elimination: Reduction to zero of the incidence of a specified disease in a defined 
geographical area as a result of deliberate efforts. Continued intervention measures are 
required. 
Eradication: Permanent reduction to zero of the worldwide incidence of infection caused 
by a specific agent as a result of deliberate efforts. Intervention measures are no longer 
needed. 
These definitions help us distinguish between “eradication” (which is always understood to be 
global) and “global elimination”, by pointing out that it is the continued need for intervention 
measures that renders elimination the less ambitious goal. That said, these definitions although 
helpful, somewhat belie the complexity still residing within disease-specific elimination goals. For 
instance, human African trypanosomiasis has been set two elimination goals of varying ambition. By 
2020, the hope is that the T.b. gambiense strain of the disease will be eliminated “as a public health 
problem”, while by 2030 it is hoped that transmission of T.b. gambiense will be reduced to zero (see 
Section 3.2 for more detail). With disease elimination, therefore, scrutinising the precise wording of 
goals is important. 
Although intuitively appealing, disease eradication is hugely challenging (hence why only one 
disease affecting humans, smallpox, has been successfully eradicated). The essential difficulty is that 
while gains in the attack phase can be achieved with relative ease and through the transplantation of 
a similar set of interventions anywhere, the closer you get to the endgame the more the challenges 
and costs escalate, and the more interventions and approaches have to be fine-tuned to local settings [16]. 
This is the experience of the Guinea-worm and poliomyelitis campaigns [19], as well as the context behind 
Dowdle and Cochi’s summation that “all eradication is ultimately local” [20] (p. 3). The central importance 
attached to diagnosis, as a means by which one might hope to understand and manage local settings, is 
now a key message coming out of the literature [21–23]. In this view, diagnostics and the data they yield 
promise to become a missing piece in the puzzle of disease elimination.  
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The scoping review that informs this article was conducted as part of the ERC-funded DiaDev 
project (www.diadev.eu, accessed on 20 May 2020). DiaDev is investigating the design and use of 
diagnostic devices in global health. Key questions for DiaDev’s elimination theme are: How does the 
goal of disease elimination inform our thinking around what, and whom, diagnosis is for? And what 
are perceived to be the ideal characteristics of the testing approaches required to achieve it? These 
questions are explored in this paper. 
2. Materials and Methods  
This paper reports on the results of a formal scoping review to look into the state of diagnostics 
for the NTDs assigned disease elimination goals in the 2012 “NTD Roadmap” [3]. Before attempting 
the review, a discourse analysis was undertaken to determine which of the 17 diseases the WHO 
originally termed “NTDs” in 2010 (WHO now supports 20 NTDs) had (a) specific disease elimination 
goals, and (b) outstanding diagnostic needs in relation to those goals [3,12]. Hence, from an initial 
group of 17 diseases, 6 were immediately discounted for having goals related only to disease control 
(dengue, buruli ulcer, cutaneous leishmaniasis, taeniasis/cysticercosis and 
echinococcosis/hydatidosis, foodborne trematode infections, and soil-transmitted helminthiasis), 2 
were discounted for having eradication goals (Guinea-worm and yaws), and two were discounted 
for having no outstanding diagnostic need (dog-mediated rabies and leprosy). This left seven NTDs, 
which became the focus of the review: Chagas disease, human African trypanosomiasis, lymphatic 
filariasis, onchocerciasis, schistosomiasis, trachoma, and visceral leishmaniasis. For the purpose of 
this paper, I only present synthesised results “by disease” for three NTDs: human African 
trypanosomiasis, onchocerciasis, and schistosomiasis. These represent a mix of diseases requiring 
Intensive Disease Management and Mass Drug Administration (concepts explained in the Results 
section), whose diagnostic capabilities range from “inadequate” to “adequate” to meet 2030 disease 
targets in the newest edition of the “NTD Roadmap” [2] (p. 34).  
The Web of Science Core Collection was searched on various dates in December 2018 and 
January 2019 to identify disease-specific publications that included topic hits on disease elimination 
and disease diagnosis. The timespan of published papers was limited to the period 1st January 2012–
31st December 2018. This time period reflects the fact that, while various World Health Assembly 
resolutions in relation to disease elimination had been put in place prior to 2012, the publication of 
the WHO’s “NTD Roadmap” in January 2012 served to collate these targets in one overarching 
document [3] and, together with the London Declaration on NTDs [13], mobilised action in pursuit 
of a bigger 2020 agenda. An overview of the search strings used in the review is provided as 
supplementary data. 
Searches were conducted using the Web of Science’s online search tool. The results were then 
exported into Microsoft Excel, where each paper’s suitability to be included in the scoping review 
was determined according to the author’s reading of the title and abstract. In total, 3465 papers were 
identified, of which 448 were included in the review (a full list of included papers is included as 
supplementary data). The breakdown of results by disease is presented in Table 2. 
Table 2. Scoping review results in aggregate and by disease. 
 Initial Search Yield (n =) Included Papers (n =) 
Chagas disease 383 45 
Human African trypanosomiasis 1271 106 
Lymphatic filariasis 1527 145 
Onchocerciasis 59 35 
Schistosomiasis 117 78 
Trachoma 28 16 
Visceral leishmaniasis 80 44 
Minus duplicates  20 
TOTAL 3465 468−20 = 448 
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The main themes identified in the included papers were analysed using the qualitative software 
package NVivo. The results were presented as a narrative synthesis. 
Due to limited time and resources, the search for this review was confined to a single database. 
It was not possible to review the abstracts for all the papers, notably conference papers. In this case, 
papers were “included” by default. 
3. Results 
The yield of included studies in the scoping review was subdivided into two categories: (1) 
papers addressing the issues facing NTD diagnosis in broad terms, i.e., presenting a global overview, 
and (2) papers addressing the foci NTDs marked out for elimination in some detail. 
3.1. Global Overview 
A close reading of the papers in this grouping revealed a general consensus around a number of 
themes and positions. Setting out whom diagnosis is targeting and the specific roles (or use cases) for 
diagnosis in light of elimination goals provides a useful backdrop to understand the peculiar 
diagnostic needs of NTD programmes. Establishing the strengths and limitations of existing testing 
approaches in the NTD field prefaces an exploration into some of the new technologies on the horizon 
and the ideal characteristics of future tests. Finally, an exploration of some of the main barriers facing 
innovation in the diagnostic field concludes this section. 
3.1.1. Setting out Whom and What Diagnosis is for in NTD Elimination Campaigns 
Several of the papers subdivided the group of NTDs being targeted for elimination into two 
categories: (a) diseases amenable to Mass Drug Administration (MDA), (“An MDA program requires 
repeated distribution of treatment to large numbers of individuals, without diagnosis” 
(Hollingsworth 2018: s240)) and (b) diseases requiring Intensive Disease Management (IDM) 
[21,22,24]. This distinction is pertinent, as it changes both the unit of intervention and the ascribed 
role of diagnosis.  
For MDA-amendable diseases like schistosomiasis, lymphatic filariasis, and onchocerciasis, the 
unit of intervention is the target population. These diseases require tests to identify and map 
populations requiring treatment and to ensure transmission is interrupted. New diagnostics are 
envisaged to play a critical role in monitoring progress towards elimination goals and for ongoing 
surveillance [21]. For these diseases, data is needed to determine when and where MDA should be 
delivered; then “the key questions are who to treat (e.g., which age group), how often to treat, and 
when treatments can be stopped” [22] (p. 241). For IDM diseases like Chagas disease and visceral 
leishmaniasis, the unit of intervention is the individual. For some IDM diseases, like human African 
trypanosomiasis (HAT), diagnosis cannot be accomplished with a single test. Instead, a diagnostic 
algorithm must be followed to confirm infection—which for HAT includes screening, parasitology, 
and disease staging [25]. There are a number of common uncertainties around IDM diseases which 
act to delay and complicate the pathway to diagnosis—for instance, long uncertain incubation 
periods and an unknown degree of transmission by asymptomatic carriers [22]. 
Hollingsworth suggests the current MDA/IDM dichotomy is “part of a shifting landscape that 
is dependent on a changing epidemiology, demography, and on the availability of new tools” [22] (p. 
242). For instance, some IDM diseases could be treated with MDA if a safer drug were developed, 
while the programmatic approach could shift to a test-and-treat campaign (or even case 
management) if the right diagnostic became available for a MDA-amenable disease or if local 
elimination was achieved. 
The traditional role of diagnosis for patient management—to rule in or out infection—is added 
to by the specific needs of elimination programmes [26]. For instance, Solomon et al. conceptualise 
four time points when MDA-amenable disease elimination programmes will require diagnosis: for 
mapping, for impact monitoring, to inform stop-MDA decision-making, and for post-elimination 
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surveillance [8]. Additional use cases for diagnostics in support of elimination programmes could 
centre on monitoring drug efficacy and drug resistance [27]. 
Several of the papers in this yield paid particular attention to the role diagnostics might play in 
disease surveillance and response [26,28–30]. Zhou, Bergquist, and Tanner define the aims of a NTD 
“surveillance and response” system as “discovery, investigation, and elimination of continuing 
transmission, the prevention and cure of infection and final substantiation of claimed eradication” 
[28] (p. 1). They underline that a key feature of surveillance response is its focus on a set of minimum 
data as opposed to classical monitoring and evaluation, with its focus on collecting all possible data. 
Research priorities for the establishment of a successful surveillance response system for NTDs 
include the development of novel tools to sensitively detect low-transmission patterns and (re-) 
emerging pathogens.  
3.1.2. Existing Diagnostic Approaches for NTDs 
In countries where laboratory infrastructure is limited, the WHO has advocated the use of 
syndromic diagnosis; and trachoma is one NTD that continues to be diagnosed clinically. As an 
approach, however, syndromic diagnosis often results in over diagnosis and treatment [26]. This may 
put a strain on limited resources, or—as is the case with trachoma—be tolerated in pursuit of disease 
elimination. 
Microscopy continues to play a central role in the diagnosis of many NTDs, including lymphatic 
filariasis and schistosomiasis, and relies on the training and expertise of professionals, as well as the 
availability of laboratories with functioning microscopes [24,31]. While microscopy for parasites is 
highly specific, its sensitivity depends on the intensity of infection. As prevalence and infection 
intensity fall—for example in response to treatment—more sensitive and/or specific tests will be 
required to secure elimination [8,24,26,28,30].  
To take the example of intestinal schistosomiasis (specifically S. mansoni), while a trained 
microscopist can identify a single schistosome egg in a faecal smear prepared by Kato–Katz, not all 
the samples from an infected person will present with eggs, particularly if the patient is suffering 
from a low-intensity infection. Examining multiple samples over consecutive days may be a tolerable 
work around in the early stages of an elimination campaign but as the elimination goal is neared, 
only a more sensitive test, preferably with high-throughput capabilities, will suffice. More specific 
tests may also be required as disease goals are met to ensure the correct pathogen is being identified. 
Five schistosoma species cause intestinal schistosomiasis, yet the current circulating cathodic antigen 
urine test is only effective at detecting S. mansoni (cross reactions of diagnostic tests to other 
pathogens is a wider concern in the literature [32–35]). A final point of clarification is that it could 
still be possible to better diagnose residual cases in elimination campaigns using existing diagnostics 
(i.e., without improving sensitivity or specificity). To manage for variations in the performance of 
existing tests, repeat testing, combining, and/or sequencing tests may help achieve the sensitivity and 
specificity required for elimination [24,31]. Equally, it could be possible to diagnose individuals with 
high-intensity infections in areas of low disease prevalence just by altering sampling strategies. 
Immunodiagnosis is already being delivered for NTDs, with rapid immunochromatographic 
tests (ICTs) offering onsite results and enzyme-linked immunoassays (ELISAs) offering higher 
sensitivity and high-throughput capability [24]. Yet, while immunodiagnosis is available for many 
NTDs, existing tests may lack sensitivity and/or specificity, and while some serological tests perform 
well (e.g., for Chagas disease), others are error prone (e.g., certain helminth species cross-react with 
antigens from other helminths); moreover, their availability may vary from one setting to another 
[31]. Peeling summarises the issue, noting that while in the last decade point-of-care tests fulfilling 
the Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free and Deliverable 
to end-users (ASSURED) criteria have become commercially available, “the quality of these tests 
varies, quality of testing is often not assured and there are few mechanisms to capture test results for 
surveillance when the testing is so decentralised” [26] (p. 385). A new generation of immunoassays 
could start to address these deficiencies. For instance, bead-based immunoassays boast increased 
sensitivity and versatility over ELISAs, as well as the potential to detect multiple pathogens using a 
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single specimen. Microfluidic immunoassays provide similar advantages whilst also offering short 
analysis times and high-throughput capabilities; they also tend to be quick and inexpensive to 
manufacture [24,26].  
Until recently molecular tools tended to be the preserve of research groups, yet there is now 
hope that molecular assays could one day replace microscopy and immunodiagnosis for some NTDs 
[31]. The advent of several point-of-care nucleic acid amplification tests (POC NAATs) like 
GeneXpert has made this more likely [24]. Yet, while GeneXpert boasts many advantages—e.g., being 
able to test for different pathogens, requiring minimal onsite expertise, and offering quick results—
it requires electricity, and without subsidisation its cartridges remain unaffordable for many low- 
and middle-income countries. Therefore, cost-efficient means of implementing novel technologies 
will need to be found if they are to maximise their potential for NTDs [26]. Already, loop-mediated 
amplification (LAMP) assays have been developed and evaluated for visceral leishmaniasis and 
human African trypanosomiasis, but as Peeling remarks, “Advocacy and investments are needed to 
apply these technologies to the control and elimination of NTDs” [26] (p. 387). 
3.1.3. Future Diagnostic Development 
According to Peeling and Mabey, “The development of appropriate diagnostics starts with 
defining target product profiles” (TPPs) [24] (p. 1792). TPPs are a description of the ideal 
specifications (performance and operational) needed for a given product, considering the needs of 
the patient and the main characteristics of the relevant health system. To think through some 
examples, as MDA-amenable diseases near elimination, large number of samples will need to be 
tested, so high-throughput diagnostics will be desirable. Meanwhile, for IDM diseases the need will 
be for point-of-care tests to reach residual or (re-)emerging infections in remote and rural 
populations. 
Many of the included papers reflect on the ideal characteristics of testing technologies to be 
deployed as disease prevalence and/or infection intensity fall in order to certify elimination and 
support post-elimination surveillance. Here again, the uniform message is that more sensitive and/or 
specific tests will be required [8,24,26,28,30]. 
A number of papers in this grouping focused on the role diagnostics might play in generating 
data to inform elimination programmes “to provide timely information on testing, trends, quality 
assurance and…to optimise supply chain management” [36] (p. 273). They point to the number of 
point-of-care devices now available that can digitise and transmit data, including a new generation 
of immunoassays and molecular technologies that can be combined with readers or mobile phones 
to collect data [24]. In addition to improving day-to-day programme management, such technologies 
have the potential to transform disease surveillance in a post-elimination context [24,26,28]. However, 
the management of digital data requires some forethought to question the kinds of systems, software, 
and IT knowledge that would be needed to collect, store, and govern it [26,36]. 
Starting with the premise that “It is neither feasible nor efficient for countries to manage 17 NTDs 
as individual programmes, each with its own range of diagnostic and surveillance tools” [36] (p. 3), 
the aspiration that a multiplex platform could one day be developed for NTDs is a common concern 
within the literature [8,36,37]. Similarities between the TPPs of seven MDA-amendable NTDs 
(trachoma, lymphatic filariasis, schistosomiasis, onchocerciasis, and soil-transmitted helminths) 
suggest that the integration of diagnostic approaches is feasible, with a multiplex platform potentially 
allowing mapping, treatment, impact monitoring, and post-elimination surveillance to be 
“coordinated to better utilise limited human and financial resources” [8] (p. 1). In considering the 
ideal characteristics of such a platform, Solomon et al. reflect on the contexts in which NTDs thrive: 
areas with little health infrastructure, varying laboratory access, and little potential for data collection 
(at least, without additional resourcing). They conclude that “The ideal integrated system might 
therefore be a portable, self-contained diagnostics platform, capable of performing multiplex assays 
for several infections of interest on one or a small number of sample types” [8] (p. 4). Since foci 
diseases vary from one population to next, a modular format would be ideal. This would have the 
added benefit of testing for co-infections like HIV and malaria. Lammie et al. also support 
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multiplexing and suggest that an existing diagnostic platform using Luminex-based antibody assays 
could be used to integrate surveillance for NTDs with the monitoring and evaluation of other public 
health efforts. Yet, while one biplex test has been developed for onchocerciasis/lymphatic filariasis 
[38,39] and another is being explored for human African trypanosomiasis/malaria [40], the dream of 
a multiplex diagnostic platform for a broad spectrum of NTDs still appears some way off. One 
stumbling block to this vision is the lack of well-characterised and validated antigens for the 
monitoring of antibody responses at the population level for several of the MDA-amenable NTDs 
[37]. 
3.1.4. Barriers to Unlocking the Potential of Diagnostics 
Despite consensus that diagnostic tools boost great potential to support NTD elimination, the 
literature highlighted a number of serious challenges. The theme of neglect and its knock-on effect 
for diagnostic innovation is addressed at some length, with the perceived lack of a commercially 
viable market for diagnostics depicted as a major barrier [21,26,31,36]. This is hampered at once by a 
lack of public and philanthropic funding—to overcome market failure—and by a research and 
development pipeline that is not sufficiently robust [21]. The upshot is that “While progress has been 
made [for NTDs] in the last decade with chemotherapy reaching a billion people in 2014, the same 
cannot be said of diagnostics…” [36] (p. 271) 
Peeling, Boeras, and Nkengasong acknowledge that “The barriers faced in implementing testing 
at point-of-care are often not technological, but constraints inherent in the health care system” [36] 
(p. 273). They expand on the myriad infrastructure requirements needed to support point-of-care 
testing. Subsequently, while it is generally accepted that the deployment of point-of-care tests can 
provide opportunities for health systems to be strengthened [36], the converse can also be true, with 
point-of-care testing exerting additional pressure on weak health systems [26]. 
Several papers made allusions to the hurdles involved in getting new diagnostic technologies 
from lab bench to end users [8,24,26]. A further two papers highlighted the “important gaps in our 
understanding of the epidemiology and control” of the NTDs that could yet alter the trajectories of 
disease programmes [22,31] (p. 17). 
3.2. By Disease 
In this section, I summarise the main diagnostic issues faced by three NTDs with elimination 
goals. In the new edition of the “NTD Roadmap”, WHO has presented the existing diagnostic 
capabilities of NTDs using a traffic light system. In this snapshot from the larger scoping review, I 
present the state of diagnosis for three NTDs, a mix of IDM and MDA-amenable diseases whose 
diagnostic capabilities are said to range from “inadequate” to “adequate” to meet their 2030 disease 
targets [2] (p. 34). 
3.2.1. Human African Trypanosomiasis 
Human African Trypanosomiasis (HAT), also known as African sleeping sickness, is a parasitic 
disease transmitted by the tsetse fly. The disease is caused by two subspecies of the African 
trypanosome: T. b. rhodesiense and T. b. gambiense. Given that T. b. rhodesiense is zoonotic, elimination 
is not deemed feasible at this time. Without treatment, HAT is ordinarily fatal. Elimination goals for 
HAT are presented in Box 2. 
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Box 2. Elimination goals for human African Trypanosomiasis 
Goal: Global Elimination 
By 2020: Eliminate T. b. gambiense as a public health problem (defined as the reduction of gambiense 
HAT incidence to less than 1 new case per 10,000 population at risk, in at least 90% of foci with 
fewer than 2000 cases reported globally). 
By 2030: Eliminate T. b. gambiense transmission to zero (defined by a reduction of HAT incidence 
to no new cases from any foci by 2030). 
The signs and symptoms of HAT are diverse and non-specific. Early diagnosis is needed to 
prevent the disease from progressing from stage 1 to stage 2 (the neurological phase). Given the 
toxicity of treatments, a confirmatory diagnosis is needed to access treatment and follows a complex 
algorithm involving screening, parasitological confirmation, and disease staging [25]. Until recently, 
the only screening tool for T.b. gambiense was the Card Agglutination Trypanosomiasis Test (CATT), 
an antibody test first developed in the 1970s. The sensitivity of CATT on blood is about 91% and its 
specificity is around 97%, making false positives an issue. Two field approaches for parasite 
detection—Mini Anion Exchange Centrifugation Technique (mAECT) and Capillary Tube 
Centrifugation (CTC)—also lack sensitivity (with mAECT achieving around 77% sensitivity and CTC 
around 56% sensitivity). For disease staging, a painful lumbar puncture is required to extract 
cerebrospinal fluid. The WHO criteria for a late-stage diagnosis is the presence of trypanosomes in 
cerebrospinal fluid or a white blood cell count of more than five cells per μL, or both [25]. Due to the 
complex and labour-intensive nature of HAT diagnosis, it has often been done by specialised mobile 
teams—engaged in active case finding—or in dedicated hospital settings.  
Historically, innovation around drugs and diagnostics has not been not been a priority for HAT, 
and it is only recently with the advent of Product Development Partnerships that new tools have been 
developed [41]. Efforts to reach the 2020 elimination goal for HAT are on course. However, it is 
significant that the first phase of the campaign has been run vertically. To achieve the goal of zero 
transmission goal by 2030, HAT services will need to be integrated into public healthcare systems. 
While new tools (e.g., rapid diagnostic tests and new oral drug fexinidazole) have contributed to the 
idea that HAT services can be integrated [42], the placement of these tools in the lower tiers of health 
systems could yet prove challenging. The literature has already begun to point to some of the 
challenges that might emerge as weak health systems attempt to integrate HAT diagnosis [43,44]. 
The years covered by the scoping review coincide with a highly productive period for HAT 
diagnostic development, with the review papers documenting the development and validation of 
“first” generation (based on native antigens) and “second’ generation” (based on recombinant 
antigens) rapid diagnostic tests for screening [45–55]. Two “first” generation tests are already 
commercially available (Standard Diagnostics, Alere, Suwan, S. Korea; Coris Bioconcept, Gembloux, 
Belguim). 
Different diagnostic approaches were also explored for parasitological detection [56–58], disease 
staging [54,59–61], and treatment follow-up [62,63]. A number of papers explored the potential of 
molecular tools for HAT, with many determining that LAMP displayed the greatest field potential at 
the current time [64–69]. 
Despite the great interest in generating new tools and testing approaches for HAT, it is 
significant that new diagnostic tools have so far done little to simplify the diagnostic tree for HAT 
(although the new drug fexinidazole should eventually remove the need for disease staging) [25]. 
Subsequently, a large portion of the literature is concerned with how best to deploy existing tools in 
support of elimination goals. In this respect, a lot of attention was assigned to screening approaches 
[43,44,70–77] and exploring testing algorithms [50,55]. 
While there is still room to improve HAT diagnosis, the tools that already exist are seen as 
“adequate” for securing elimination in the newest “NTD Roadmap”, requiring only some 
“modifications” to reach the 2030 target [2] (p. 34). That said, an aspiration for a new simplified and 
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field-adapted diagnostic tool (one that does not require confirmatory testing by microscopy) is 
reported. 
3.2.2. Onchocerciasis 
Onchocerciasis is a chronic parasitic disease caused by the filarial worm, Onchocerca volvulus, 
and is transmitted through bites of infected (Simulium) blackflies. It is the second leading cause of 
preventable blindness worldwide. Ivermectin is the main treatment for onchocerciasis. While it has 
a good activity against microfilariae, it does not kill adult O. volvulus worms, which can go on to 
repopulate microfilariae several months after treatment. Nevertheless community-directed treatment 
with ivermectin (CDTI) (typically once per year) is deemed an effective strategy for reducing 
microfilariae prevalence and the concentration of microfilariae in the target organs (skin and eyes) 
[78].  
The impact of African Programme for Onchocerciasis Control (now replaced by the Expanded 
Special Project for Elimination of NTDs) was impressive, reducing disability-adjusted life year losses 
by 80% in foci countries [79]. However, such gains could yet be lost if CDTI is discontinued 
prematurely. The need to guide decision-making with regard to treatment has therefore created 
multiple entry points for diagnostics to help secure elimination: for mapping, mid-course monitoring 
and evaluation, determining where transmission has been interrupted (i.e., for stop-MDA decisions), 
and post-CDTI surveillance [78]. Elimination goals for onchocerciasis are presented in Box 3. 
Box 3. Elimination goals for onchocerciasis  
Goal: Regional Elimination 
The Onchocerciasis Elimination Program of the Americas (OEPA) began in 1992 with the goal of 
elimination at the outset. The target date for elimination of onchocerciasis transmission in the 
Region has been set as 2022. Four of the six endemic countries have already achieved elimination. 
In 2012, WHO’s “NTD Roadmap” set a goal of elimination where feasible by 2020. The African 
Programme for Onchocerciasis Control advanced the goal to elimination in 80% of countries by 
2025. 
The tests and strategies that once proved useful for identifying priority areas for onchocerciasis 
interventions are unlikely to prove adequate for meeting elimination goals [78]. For instance, clinical 
examination has low sensitivity in areas of low prevalence, while the diethylcarbamazine (DEC) 
patch test and skin snip microscopy both lack sensitivity after treatment with ivermectin (which 
reduces the number of microfilariae in the skin to zero or near to zero). Furthermore, there is no point-
of-care diagnostic that can distinguish between active and past infection, nor is there a test that can 
detect fecund adult female parasites in the human population (which could restart reproduction once 
MDA is stopped). Subsequently, a major focus of the literature centres on how diagnostics might 
support the four functions determined by the elimination goal. At point-of-care, antibody testing 
shows promise for supporting elimination programmes where the prevalence is high. ELISAs 
incorporating the Ov16 antigen are already widely used in elimination campaigns, while two rapid 
diagnostic tests based on Ov16 have become commercially available: a monoplex and a biplex for 
onchocerciasis and lymphatic filariasis (Standard Diagnostics, Suwan, S. Korea). However, WHO 
guidelines recommend further evaluation of the rapid diagnostic tests prior to their use in stop-MDA 
assessments [80].  
In order to verify elimination, more sensitive and specific testing approaches are still required 
[39,78,81–83], and could—in theory—be achieved using a combination of tests [39].  
Many papers sought to explore new testing approaches or ways to incrementally improve 
current methods [39,84–91]. In addition, common practice and official guidance were questioned 
[39,78,92].  
The general consensus to emerge from the review is that the diagnostic arsenal for onchocerciasis 
is deficient. This aligns with the revised “NTD Roadmap”, which determines that existing tools for 
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onchocerciasis require “major modifications” or might be considered “inadequate to reach 2030 
targets” [2] (p. 34). As a first point of call, WHO and its partners would like to see the Ov16 monoplex 
and biplex onchocerciasis/lymphatic filariasis tests optimised, and a confirmatory diagnostic 
developed for use in low-prevalence settings to support a range of use cases. 
3.2.3. Schistosomiasis 
Schistosomiasis, also known as bilharzia, is caused by blood flukes (trematode worms) of the 
genus Schistosoma. Infective larvae grow in an intermediate host (fresh-water snails) before 
penetrating the skin of the human host. Mature adult worms reside in the mesenteric (S. mansoni and 
S. japonicum) or pelvic (S. haematobium) veins, where female worms lay eggs that are later secreted in 
stools or urine. Eggs trapped in the surrounding tissues and organs cause inflammatory immune 
responses that result in intestinal, hepato-splenic, or urogenital disease [93]. Seventy-eight countries 
are endemic for schistosome infections, with different species of schistosomes affecting different 
regions. S. haematobium and S. mansoni are the main causative agents. The distribution of 
schistosomiasis is highly focal due to the fact that transmission relies on specific intermediary hosts 
and activities that expose humans to infection [94]. Elimination goals for schistosomiasis are 
presented in Box 4. 
Box 4. Elimination goals for schistosomiasis  
Goal: Regional Elimination 
2015 regional elimination goals apply to the Eastern Mediterranean region, the Caribbean, 
Indonesia and the Mekong River Basin. 
2020 regional elimination goals apply to the Region of the Americas, the Western Pacific Region 
and in selected countries in the African region. 
Schistosomiasis demonstrates the complications that can reside behind an ostensibly simple 
MDA-based programme. The drug praziquantel is largely donated and is being administered in vast 
quantities, but the drug is not perfect; there are concerns around drug resistance, unpleasant side 
effects can impede uptake, and reinfection following treatment is swift. Diagnosis has therefore come 
to play a central role in better targeting elimination programmes that are being deployed at the 
community, individual, and environmental levels to assess reductions in disease, infections, and 
parasite transmission [95]. However, there are no simple diagnostic solutions. 
The mainstay of schistosomiasis diagnosis is based on the detection of parasite eggs in urine or 
in faeces, for instance using urine filtration or examining faecal smears prepared by the Kato–Katz 
technique (microhaematuria has also been used as a proxy for urogenital schistosomiasis in some 
settings). However, because the number of excreted eggs is often low and shows much day-to-day 
fluctuation, these methods are not considered sensitive enough to support elimination goals in low-
endemicity settings. Serology—the testing of antibody responses—provides high levels of sensitivity 
and specificity but does not disclose the intensity of infection, and cannot differentiate between active 
and past infection. To achieve even higher sensitivity and identify active infection, research has 
concentrated on the amplification of pathogen DNA using techniques based on polymerase chain 
reaction or LAMP. High sensitivities capable of determining active infection have also been achieved 
with assays for the detection of circulating anodic antigen (CAA) and circulating cathodic antigen 
(CCA) in serum or urine [96], including a commercially available CCA test (Rapid Medical 
Diagnostics, Pretoria, South Africa). 
A number of papers reviewed the available diagnostic approaches for schistosomiasis, finding 
room for improvement with each [95–101]. Subsequently, the emerging consensus is for a stratified 
approach, by which difference test combinations are deployed for different use cases and tailored to 
the exigencies of national programmes [96,102–106]. In this context, the correct question for 
schistosomiasis elimination is not “What is the best tool?” but “What are the best diagnostic 
methods?” and how these apply to each of the stages of control and elimination [96,102]. Several 
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papers set out to address these questions through the development of Target Product Profiles [8,106–
108]. 
According to the new “NTD Roadmap”, although diagnostic tools to support the elimination of 
schistosomiasis already exist, across the board they are require “major modifications” or are deemed 
“inadequate to reach 2030 targets” [2] (p. 34). Ideally, WHO and its partners would like to see the 
development of a standardised, sensitive, point-of-care diagnostic for use in various prevalence 
settings and for all schistosome species.  
4. Discussion 
Where once the role of diagnosis in guiding clinical decision-making in relation to individual 
patients was assumed (and conceptualised as linear), today a wealth of literature exists to challenge 
this position. Not only is the idea that diagnosis informs treatment pathways questionable, but the 
notion that diagnosis is something that happens to an individual is changing. The exigencies of 
disease NTD elimination programmes exemplify both shifts. Individuals may still retain their central 
position at the heart of IDM programmes like HAT and visceral leishmaniasis, but for diseases 
amendable to MDA, like schistosomiasis or onchocerciasis, the focus of diagnosis is currently on the 
collective. Furthermore, a positive diagnosis may not result in access to treatment if programmatic 
thresholds are not met. Yet, the IDM/MDA dichotomy is not set in stone and could shift as new tools 
are developed or if MDA programmes move to test and treat strategies. 
In support of elimination goals, the proposed uses of diagnostics have grown. For IDM diseases, 
the foremost need is for confirmatory diagnosis, but in theory other functions would support disease 
programmes—tests of drug efficacy, tests of cure, and tests capable of picking up emerging drug 
resistance. For MDA-amendable diseases, there are at least four entry points (termed use cases) for 
diagnosis: disease mapping, impact monitoring, stop-MDA decision-making, and surveillance 
response. However, assays testing drug efficacy and looking for resistance would be helpful add-ons.  
While initially the yield of included studies was sub-divided into two pots for practical 
purposes, one consequence of synthesising the results in this way has been to reveal a disconnect 
between the speculative nature of debate in the “global overview” papers—which to some extent 
assume that better diagnostics are both needed and coming—and the messy reality of the testing 
approaches disease programmes are currently utilising. This is well exemplified for the post-
elimination scenario in relation to the surveillance and response systems. Here, we are told, 
programmes will need testing approaches that are sufficiently specific and sensitive, preferably 
supported by mobile and electronic technologies, and—for IDM diseases—deployable at the point-
of-care. Yet, the review of diagnostic needs “by disease” suggests we are very far from this vision, 
and this is confirmed by the overview provided by WHO in the new “NTD Roadmap” [2]. Disease 
programmes are attempting to further elimination goals with less than perfect diagnostic approaches. 
There are few “gold standards”. In a bid to address the many deficiencies and unknowns, 
programmes might choose to conduct repeat testing and/or deploy tests in combinations and 
algorithms. However, official guidance over which tests to deploy, when, and in what combination 
is not always available and can be subject to change. The use of the humble microscope and skilled 
technician retains a centrally important role in this mix. 
Diagnosis appears to offer certainty to disease programmes (and the donors supporting them) 
as they approach elimination goals, but this review speaks largely to uncertainty. What is meant by 
disease elimination varies by disease; the distinction between IDM and MDA-amendable NTDs could 
shift if the right tool was devised; mapping approaches, sampling frames, and thresholds for starting 
MDA are all subject to revision; epidemiological knowledge is known to be wanting; and tests that 
perform well in the lab for unknown reasons fail in the field. One response to dealing with such 
uncertainty is to declare a need for new technologies. Not just new and better tests, but technology 
that could support existing approaches by transmitting, storing, and analysing diagnostic data; and 
to quality check results (RDT readers, video of microscope views). Where the funding might be found 
to support product innovation in the field of diagnostics is unclear at this time.  
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A lot of the research picked up in the review related to basic research or tools and approaches 
with little field potential. This feels like a missed opportunity. The review did pick up draft Target 
Product Profiles for NTDs like Chagas disease and schistosomiasis [8,106,108,109]. Target Product 
Profiles could and should play a role in aligning research to real world uses to maximise the utility 
of limited resources, but only if they are informed by the patients who need them and the health 
systems that will use them. As Tambo et al. have stated, “a deeper understanding of which tools and 
strategies are most suitable to achieve elimination…are needed” [29] (p. 8). 
5. Conclusions 
This review has upheld the growing consensus that diagnostic technologies will need to play a 
pivotal role in determining the success of NTD elimination goals. Yet, it has also concluded that there 
remains substantial work to do. To drive research and attract investment, the field of diagnosis for 
NTD elimination urgently needs a guiding framework. It is pertinent, therefore, that in 2019 the WHO 
convened a Diagnostic Technical Advisory Group to assess and prioritise diagnostic needs for the 
portfolio of NTDs the WHO supports. As part of its work, the group will review existing Target 
Product Profiles and support the development of new ones wherever critical gaps are identified [110].  
Just as early NTD campaigning set about drumming up support for MDA campaigns [10], now 
donors (including pharmaceutical companies) will need to be convinced of the merit of supporting 
the deployment, refinement, and development of diagnostic technologies in support of NTD 
elimination goals. The argument is actually very compelling; diagnostics in every use case are a 
means of better targeting and thus rationalising resources. Moreover, they will play a central role in 
sustaining programmatic successes in relation to disease elimination, which will require surveillance 
and response systems that can point to new and re-emerging infections. The incorporation of several 
NTD tests in the second edition of the Essential Diagnostics List in 2019 was a useful first step toward 
building this messaging [111]. 
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